For Your Information: March 15, 1996
The Federal Trade Commission today announced the following actions. The FTC staff contact is Dan Ducore, 202-326-2526.
Applications for prior approval of transactions: The FTC has received an application for prior approval of a divestiture from the following. The application will be subject to public comment for 30 days, until April 15.
- Glaxo Wellcome plc, a British firm, has applied for FTC approval to divest the worldwide assets relating to the research, development, manufacture, distribution and sale of a migraine headache medicine to Zeneca Limited, which is based in London, England. The assets relate to 311C90, a non-injectable 5HTID agonist formerly owned by Wellcome plc. The divestiture is required under a 1995 consent order settling charges over Glaxo's acquisition of Wellcome, and is intended to restore competition for the medicine that allegedly was injured by the acquisition. Glaxo had developed and marketed the only other 5HTID agonist -- sumatriptan -- for migraine treatment at the time of the acquisition (see March 16, 1995 news release regarding the consent order; Docket No. C-3586.)
Commission action regarding petitions to reopen and modify FTC orders: Following a public comment period, the FTC has ruled on the following petition:
- The FTC has granted the petition of Adobe Systems Incorporated, of Mountain View, California, thereby ending Adobe's obligation to obtain FTC approval before acquiring an interest in a firm that develops or sells professional-illustration software for the Macintosh or Power Macintosh. Adobe still is required to notify the FTC in advance of acquisitions of professional illustration software. The prior-approval provision was included in a 1994 consent order that settled charges over the merger of Adobe and Aldus Corporation, and that was designed to restore and maintain competition in the market for professional-illustration software for use on the Apple Macintosh and Power Macintosh computers (see July 27, 1994 news release regarding the consent order; Docket No. C-3536; Commission vote 5-0 on March 13, 1996).
Comments on the Glaxo Wellcome application should be addressed to the FTC, Office of the Secretary, 6th Street and Pennsylvania Avenue, N.W., Washington, D.C. 20580. Copies of all documents referenced above are available from the FTC's Public Reference Branch, Room 130, at the same address; 202-326-2222; TTY for the hearing impaired 1-866-653-4261. To find out the latest news as it is announced, call the FTC NewsPhone recording at 202-326-2710. FTC news releases and other materials also are available on the Internet at the FTC's World Wide Web site at: http://www.ftc.gov